Retrophin (RTRX) Misses Q3 EPS by 23c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Retrophin (RTRX) Misses Q3 EPS by 23c, Revenues Miss

Retrophin Reports Third Quarter 2018 Financial Results

November 1, 2018 4:01 PM EDT

Pivotal programs enrolling towards first data readout in 2019

Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019

Completed offering of $276 million convertible senior notes due 2025

SAN DIEGO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2018 financial results and provided a corporate update.

Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase-associated neurodegeneration (PKAN) continues toward completion of enrollment; top-line data expected in second half of... More